スタチン市場：タイプ、薬剤クラス別、用途、エンドユーザー別-2025～2030年の世界予測

スタチン市場は、2023年に316億1,000万米ドルと評価され、2024年には333億米ドルに達すると予測され、CAGR 5.85%で成長し、2030年には470億8,000万米ドルに達すると予測されています。

スタチン市場は主に、肝臓でのコレステロール生産に極めて重要な酵素HMG-CoA還元酵素を阻害するコレステロール低下薬に焦点を当てています。これらの薬剤は高脂血症の治療において重要であり、心血管リスクの低減を目指し、それによって世界の心臓病率の高騰に対処しています。スタチン市場の必要性は、高コレステロール値を示す患者の一次予防と二次予防の両方に幅広く応用されることで、心血管疾患を管理するという公衆衛生上の要求が高まっていることに起因しています。最終用途は病院、クリニック、家庭配合に及び、市場消費の大きな原動力となっています。市場の力学は、高齢化、座りがちなライフスタイル、コレステロール値管理の重要性に対する意識の高まりに大きく影響され、成長を牽引しています。さらに、併用療法や個別化医療の登場により、有効性と患者の服薬アドヒアランスを高める機会が生まれつつあります。特許失効後のジェネリック医薬品の急増も、市場のアクセシビリティを拡大すると予想されます。しかし、副作用、薬剤相互作用、PCSK9阻害剤のようなスタチン以外の薬剤の存在といった制約が課題となっています。厳しい規制環境や、より少ない副作用で心血管系への効果を期待できる新たな代替治療との競合が、市場の成長をさらに阻害しています。イノベーションのためには、副作用を最小限に抑えた次世代のスタチンの開発と、患者の転帰とアドヒアランスを追跡するためのデジタルヘルスソリューションの導入に焦点を当てるべきです。その他の有望なセグメントとしては、血中脂質値に影響を与えるリポ蛋白因子をより精緻に標的化できるバイオテクノロジーの進歩があり、優れた治療効果が得られる可能性があります。市場を理解するには、予防医療へのシフトと、心血管の健康を徹底したいという消費者の志向の高まりを認識することが必要であり、これによって企業は革新的なドラッグとデリバリーシステムを活用する機会を得ることになります。結論として、市場は課題に直面しているもの、戦略的イノベーションと規制状況への対応により、スタチン領域で大きな事業成長が期待できます。

市場力学：急速に進化するスタチン市場の主要市場洞察を公開

スタチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患罹患率の増加
  • 市販薬（OTC）に対する消費者の嗜好の高まり
  • 健康的なライフスタイルの維持に対する消費者の意識の高まりによるスタチンの需要拡大
• 市場抑制要因
  • 新興国における代替医薬品への嗜好の高まり
• 市場機会
  • 新規スタチン開発のための研究開発活動の成長
  • 手頃な価格で効果的なコレステロール維持ソリューションに対する需要の高まり
• 市場課題
  • スタチンの副作用に関する懸念

ポーターのファイブフォース：スタチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、スタチン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：スタチン市場における外部からの影響の把握

外部マクロ環境要因は、スタチン市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：スタチン市場における競合情勢の把握

スタチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：スタチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、スタチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：スタチン市場における成功への道筋を描く

スタチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に慢性疾患の発症率が増加
    • 消費者の市販薬（OTC）に対する嗜好の高まり
    • 健康的なライフスタイルを維持することに対する消費者の意識の高まりにより、スタチンの需要が高まっている
  • 抑制要因
    • 新興国における代替医療への嗜好の高まり
  • 機会
    • 新しいスタチン開発のための研究開発活動の拡大
    • 手頃な価格で効果的なコレステロール維持ソリューションへの需要の高まり
  • 課題
    • スタチンの副作用に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 スタチン市場：タイプ別

• イントロダクション
• 天然スタチン
• 合成スタチン

第7章 スタチン市場：薬剤クラス別

• イントロダクション
• アトルバスタチン
• フルバスタチン
• ロバスタチン
• ピタバスタチン
• ロスバスタチン
• シンバスタチン

第8章 スタチン市場：用途別

• イントロダクション
• 発作
• 心血管疾患
• 糖尿病
• 心臓発作
• 炎症
• 生活習慣病
• 肥満

第9章 スタチン市場：エンドユーザー別

• イントロダクション
• クリニック
• 病院

第10章 南北アメリカのスタチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋のスタチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのスタチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AccuBioTech Co., Ltd.
• Amgen Inc.
• AstraZeneca PLC
• Aurobindo Pharma Ltd.
• Becton, Dickinson and Company
• Biocon Limited
• bioMerieux S.A.
• Centrient Pharmaceuticals Netherlands B.V.
• Concord BIoTech Limited
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffman-La Roche AG
• GlaxoSmithKline PLC
• Grifols, S.A.
• Merck & Co., Inc.
• Nova Biomedical
• Novartis AG
• Pfizer Inc.
• Quidel Corporation
• Siemens AG
• Terumo Corporation
• Thermo Fisher Scientific, Inc.
• Trinity BIoTech PLC

LIST OF FIGURES

• FIGURE 1. STATINS MARKET RESEARCH PROCESS
• FIGURE 2. STATINS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. STATINS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. STATINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. STATINS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. STATINS MARKET DYNAMICS
• TABLE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL STATINS MARKET SIZE, BY NATURAL STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL STATINS MARKET SIZE, BY SYNTHETIC STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL STATINS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL STATINS MARKET SIZE, BY FLUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL STATINS MARKET SIZE, BY LOVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL STATINS MARKET SIZE, BY PITAVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL STATINS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL STATINS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL STATINS MARKET SIZE, BY ATTACKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL STATINS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL STATINS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL STATINS MARKET SIZE, BY HEART STROKES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL STATINS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL STATINS MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL STATINS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL STATINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL STATINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES STATINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. CHINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. CHINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. CHINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. INDIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. INDIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. ITALY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. ITALY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. ITALY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. POLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. POLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. POLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. QATAR STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. QATAR STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. QATAR STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. STATINS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. STATINS MARKET, FPNV POSITIONING MATRIX, 2023

The Statins Market was valued at USD 31.61 billion in 2023, expected to reach USD 33.30 billion in 2024, and is projected to grow at a CAGR of 5.85%, to USD 47.08 billion by 2030.

The statin market focuses primarily on cholesterol-lowering medications that impede the enzyme HMG-CoA reductase, pivotal in cholesterol production within the liver. These drugs are critical in treating hyperlipidemia, aiming at cardiovascular risk reduction, thereby addressing soaring global heart disease rates. The statin market's necessity stems from the growing public health demand to manage cardiovascular diseases, with broad applications in both primary and secondary prevention for patients exhibiting high cholesterol levels. End-use spans hospital settings, clinics, and household prescriptions, fueling significant market consumption. Market dynamics are heavily influenced by an aging population, sedentary lifestyles, and increasing awareness of the importance of managing cholesterol levels, driving growth. Additionally, opportunities are emerging from the advent of combination therapies and personalized medicine, which could enhance efficacy and patient adherence. A surge in generic drugs post-patent expiration is also expected to expand market accessibility. However, limitations such as adverse side effects, drug interactions, and the presence of non-statins like PCSK9 inhibitors pose challenges. Market growth is further impeded by stringent regulatory environments and competition from emerging alternative treatments that promise cardiovascular benefits with fewer side effects. For innovation, focus should be on developing next-generation statins with minimal side effects and incorporating digital health solutions to track patient outcomes and adherence. Other promising areas include biotechnological advancements allowing for more refined targeting of lipoprotein factors influencing blood lipid levels, potentially achieving superior therapeutic outcomes. Understanding the marketplace entails recognizing a shift towards preventative healthcare measures and growing consumer inclination for thorough cardiovascular health, presenting businesses with opportunities to harness innovative drugs and delivery systems. Conclusively, while the market faces challenges, strategic innovation and responsiveness to regulatory landscapes can yield considerable business growth in the statin domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Statins Market

The Statins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in the incidence of chronic diseases globally
  • Rising consumer preference for over-the-counter (OTC) drugs
  • Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
• Market Restraints
  • Increasing preference for alternative medicines in emerging economies
• Market Opportunities
  • Growth in R&D activities for newer statin development
  • Emerging demand for affordable and effective cholesterol-maintaining solutions
• Market Challenges
  • Concerns associated with side-effects of statins

Porter's Five Forces: A Strategic Tool for Navigating the Statins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Statins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Statins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Statins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Statins Market

A detailed market share analysis in the Statins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Statins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Statins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Statins Market

A strategic analysis of the Statins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Statins Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Ltd., Becton, Dickinson and Company, Biocon Limited, bioMerieux S.A., Centrient Pharmaceuticals Netherlands B.V., Concord Biotech Limited, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche AG, GlaxoSmithKline PLC, Grifols, S.A., Merck & Co., Inc., Nova Biomedical, Novartis AG, Pfizer Inc., Quidel Corporation, Siemens AG, Terumo Corporation, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Statins Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Natural Statins and Synthetic Statins.
• Based on Drug Class, market is studied across Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Rosuvastatin, and Simvastatin.
• Based on Application, market is studied across Attacks, Cardiovascular Diseases, Diabetes, Heart Strokes, Inflammation, Lifestyle Diseases, and Obesity.
• Based on End-User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the incidence of chronic diseases globally
    • 5.1.1.2. Rising consumer preference for over-the-counter (OTC) drugs
    • 5.1.1.3. Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
  • 5.1.2. Restraints
    • 5.1.2.1. Increasing preference for alternative medicines in emerging economies
  • 5.1.3. Opportunities
    • 5.1.3.1. Growth in R&D activities for newer statin development
    • 5.1.3.2. Emerging demand for affordable and effective cholesterol-maintaining solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with side-effects of statins
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Statins Market, by Type

• 6.1. Introduction
• 6.2. Natural Statins
• 6.3. Synthetic Statins

7. Statins Market, by Drug Class

• 7.1. Introduction
• 7.2. Atorvastatin
• 7.3. Fluvastatin
• 7.4. Lovastatin
• 7.5. Pitavastatin
• 7.6. Rosuvastatin
• 7.7. Simvastatin

8. Statins Market, by Application

• 8.1. Introduction
• 8.2. Attacks
• 8.3. Cardiovascular Diseases
• 8.4. Diabetes
• 8.5. Heart Strokes
• 8.6. Inflammation
• 8.7. Lifestyle Diseases
• 8.8. Obesity

9. Statins Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Hospitals

10. Americas Statins Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Statins Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Statins Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AccuBioTech Co., Ltd.
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Aurobindo Pharma Ltd.
• 6. Becton, Dickinson and Company
• 7. Biocon Limited
• 8. bioMerieux S.A.
• 9. Centrient Pharmaceuticals Netherlands B.V.
• 10. Concord Biotech Limited
• 11. Danaher Corporation
• 12. DiaSorin S.p.A.
• 13. F. Hoffman-La Roche AG
• 14. GlaxoSmithKline PLC
• 15. Grifols, S.A.
• 16. Merck & Co., Inc.
• 17. Nova Biomedical
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Quidel Corporation
• 21. Siemens AG
• 22. Terumo Corporation
• 23. Thermo Fisher Scientific, Inc.
• 24. Trinity Biotech PLC